Trading for the period was in line with the Board's expectations, with total sales volumes ahead of the equivalent period last year, continuing the momentum delivered in H1.
The Devro 100 programme continues to progress well, with actions on track to deliver the anticipated cost savings for the year.
The Board's expectations for the year ending 31 December 2017 remain unchanged.